Intraocular Pressure Elevations Are Not Necessarily Glaucoma: Perspectives On Ozurdex Treatment.
OZURDEX (Allergan) is approved for the treatment of diabetic macular edema (DME), macular edema following branch or central retinal vein occlusion (BRVO or CRVO), and noninfectious posterior segment uveitis.1 Elevated IOP is a known adverse reaction associated with ophthalmic steroids, including OZURDEX.1 All patients treated with OZURDEX are monitored for elevated IOP and managed with eye drops, and, rarely, with surgery.1 In clinical practice, concerns about elevated IOP remain.2 We gathered a group of retina specialists and a glaucoma specialist to discuss the differences between elevated IOP and glaucoma, and how to assess each in patients with DME. The content of this supplement reflects the perspectives and experiences of the participants.
Wolfe JD. Intraocular pressure elevations are not necessarily glaucoma: Perspectives on ozurdex treatment. Retina Today Supplement, May/June 2017.